On October 19, 2026 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, reported a conference call and webcast to review clinical data from the ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations in conjunction with the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The conference call and webcast will take place on Friday, October 23, 2026, at 8:00 am ET. ORIC leadership plans to have Dr. Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine, join the call to share his perspective on the enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and an audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
Full abstracts of the three poster presentations are available for public viewing via the ESMO (Free ESMO Whitepaper) Congress website, here. Posters will be available for public viewing via the ESMO (Free ESMO Whitepaper) Congress website on October 23, 2026.
Poster presentation details:
Title: Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective
EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations
Presentation Number: 2627P
Session Date & Time: Monday, October 26, 2026; 12:00 – 12:45 p.m. CET
Session Title: Metastatic NSCLC
Title: Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With
Darolutamide: A Global Phase 3 Study in mCRPC Patients
Previously Treated With Abiraterone Acetate (Himalayas-1)
Presentation Number: 2303TiP
Session Date & Time: Friday, October 23, 2026; 3:15 – 4:00 p.m. CEST
Session Title: Metastatic Prostate Cancer
Title: Rinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances
Luminal Fate and AR Signaling While Restricting Lineage
Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples From Patients with mCRPC
Presentation Number: 1128eP
Session Title: Developmental Therapeutics
(Press release, ORIC Pharmaceuticals, OCT 19, 2026, https://investors.oricpharma.com/news-releases/news-release-details/oricr-pharmaceuticals-host-conference-call-webcast-review [SID1234673571])